Drug Profile
PEC Direct
Alternative Names: PEC-Direct; VC 02 combination product; VC-02; VC-02 Combination ProductLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator BetaLogics; ViaCyte Inc
- Developer ViaCyte Inc
- Class Pluripotent stem cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Type 1 diabetes mellitus
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for clinical-Phase-Unknown development in Type-1 diabetes mellitus in Europe (SC, Implant)
- 19 Oct 2023 ViaCyte completes a phase I/II trial in Type 1 diabetes mellitus in Belgium, Canada, USA (SC) (NCT03163511)
- 23 Feb 2022 Phase I/II trial is still ongoing for Type 1 diabetes mellitus in USA, Canada and Belgium (NCT03163511)